Ready for the Change? – PTI Provides Guidance on New EU Clinical Trial Regulation
News Nov 26, 2015
Pharmaceutical Training International (PTI), the leading supplier of online and public event-based training courses for the pharma, biotech and medical device sectors, is providing detailed guidance on the new EU Clinical Trial Regulation (EU-CTR) which applies from 28th May 2016. Making sure clinical trial and regulatory affairs professionals are up-to-date and prepared, PTI is hosting a convenient and cost-effective 2-hour webinar e-course at 2:30 PM (UK) on Wednesday 2nd December. Industry expert Adriaan Fruijtier – Director Regulatory Affairs, CATS Consultants GmbH, and formerly Head of the Oncology Group within Global Regulatory Affairs at Bayer AG and Bayer Corporation - will host this event.
The EU-CTR replaces the EU Clinical Trials Directive and is designed to improve harmonisation on conducting clinical trials of medicinal products for human use throughout the EU. It brings with it significant procedural changes for both trial authorisation and conduct for which individuals and organisations must be prepared. In PTI’s webinar e-course titled ‘Guidance on the New Clinical Trial Regulation’ Adriaan Fruijtier will provide a comprehensive examination of the new regulation. He will cover the scope, authorisation procedures, low intervention clinical trials, the EU portal and database, transparency requirements, key timelines and milestones, and a helpful comparison between the new regulation and the existing directive. With over 20 years’ experience in pharma regulatory affairs, Adriaan will also be available for a valuable live question and answer session at the end of the webinar.
“This really is essential information for anyone working in clinical trials and regulatory affairs,” said PTI’s Managing Director, Rosie Bernard. “With this webinar e-course we wanted to make it as easy as possible for professionals to access the most up-to-date and useful guidance to ensure a smooth transition to the EU-CTR next year. Adriaan is an expert with a great deal of experience in pharma regulatory affairs, ranging from the European Medicines Agency to the likes of Glaxo and Novartis, so I can’t think of anyone better placed to deliver this guidance. It’s also a great opportunity for professionals to address specific queries with him personally in the live Q&A session.”
Be prepared for the new EU-CTR. Learn more and register for this webinar e-course.
For more information, please visit the Further Information link below.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
‘Mini Tumors’ from Patient Samples Could Help Personalize Cancer Drug TreatmentNews
Testing cancer drugs on miniature replicas of a patient’s tumour could help doctors tell in advance which treatments will work, a major new study reports.READ MORE